Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma

Clin Lymphoma Myeloma. 2006 Jan;6(4):342-7. doi: 10.3816/CLM.2006.n.011.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Burkitt Lymphoma / immunology
  • Burkitt Lymphoma / therapy*
  • Female
  • Herpesvirus 4, Human* / immunology
  • Hodgkin Disease / immunology
  • Hodgkin Disease / therapy*
  • Hodgkin Disease / virology
  • Humans
  • Immunotherapy, Adoptive*
  • Male
  • Nuclear Proteins / immunology*
  • Phosphoproteins / immunology*
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Cytotoxic / transplantation*

Substances

  • Nuclear Proteins
  • Phosphoproteins
  • latent nuclear antigen (LNA)